Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2230 participants.
Also called NCT02666664
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,230 participants
- Sponsor
- Registry
-
NCT02666664 -
2015-004136-36
-
- Main results
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- Other papers using this trial's data
- Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, Netherlands, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02666664. Randomized; triple masking; primary purpose treatment. Start 2016-01-21 (actual); primary completion 2018-02-21 (actual). Results posted on 2020-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
- Condition
- Hypercholesterolemia
- Condition
- Atherosclerotic Cardiovascular Diseases
- Intervention (Drug)
- ETC-1002
- Intervention (Drug)
- Placebo
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02666664- Content hash
e2620acbca2c57f8adc998bb3060e0672654254aee79e48f83bc6ba2ca556cad